The study of pharmacological countermeasures for high altitude

United States Army Research Institute of Environmental Medicine is commencing recruitment for the clinical trial of the Pharmacological Countermeasures for High Altitude.

The condition is Hypobaric Hypoxia.

A new clinical trial is recruiting patients in the following locations: United States.

The trial officially began on the May 27, 2022 and is planned to complete on August 30, 2022.

The aim of this randomized, double-blind study is to determine whether erythropoietin (Procrit) and acetazolamide: 1) mitigates altitude-induced decrements in performance at moderate altitude (3,000 m) and 2) mitigates altitude-induced decrements in performance and reduce acute mountain sickness during prolonged exposure to high altitude (4,300 m; 15 days). Volunteers will complete 5 study phases: Phase 1) sea level baseline testing and a moderate altitude exposure; Phase 2) 4 week study intervention - randomly assigned to receive erythropoietin or placebo); Phase 3) 3 1/2 days of acetazolamide and a moderate altitude exposure; Phase 4) high altitude acclimatization - 15 days at Pikes Peak; and Phase 5) two week deacclimatization. Test battery include VO2peak, 3.2 km treadmill time trial, measures of gas exchange and ventilation during rest and exercise, and blood collection.

University of Puget Sound is the collaborator in this clinical trial.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05300477.

Clinical Research News

Kommende kliniske forsøg

3